Investing Profile

Dan Becker

InvestorVC
Managing Director at Access Biotechnology
accessbio-tech.comNew York, New York
Photo of Dan Becker, Managing Director at Access Biotechnology

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
Access Biotechnology Managing Director
$100K - $5.0M
$1.5M
13
CompanyStageDateRound SizeTotal Raised
Day One Biopharmaceuticals
Post Ipo EquityJul 2024$180M
Series BFeb 2021$130M
Series AMay 2020$60M
$370M
Co-investors: Julie Grant (Canaan Partners), Michael Gladstone (Atlas Venture), Derek DiRocco (RA Capital)
GRO Biosciences
Series BJul 2024$60M
$91M
Co-investors: Geoffrey Smith (Digitalis Ventures), Kevin Bitterman (Atlas Venture), Ameena El-Bibany (Artis Ventures (AV)), Russ Wilcox (Pillar VC), Dror Berman (Innovation Endeavors)
Mariana Oncology
Series BSep 2023$180M
Series ADec 2021$75M
$250M
Co-investors: Kevin Bitterman (Atlas Venture), Geert-Jan Mulder (Forbion), Josh Resnick
Hemab
Series BFeb 2023$140M
$140M
Co-investors: Uya Chuluunbaatar (Amzak Health Investors), Christine Borowski (Access Biotechnology)
Zurp
Pre SeedJan 2023$5M
$5M
Co-investors: Amy Wu (Menlo Ventures), Lenny Rachitsky (AirAngels), David Weisburd (10X Capital), Julia Lipton (Awesome People Ventures), Pascal Unger (Darling Ventures), Dhani Jones (QEY Capital), Daniel Darling (Darling Ventures), Scott Belsky, Siqi Chen, Shane Neman, Niklas Jansen, Baron Davis, Bobby Goodlatte, Nik Sharma
ACELYRIN
Series CSep 2022$300M
$560M
Co-investors: Richard Gaster (venBio), Beth Seidenberg (Westlake Village BioPartners), Sean Harper
Curie Therapeutics
Series ADec 2021$75M
$75M
Co-investors: Kevin Bitterman (Atlas Venture)
DTx Pharma
Series BMar 2021$100M
$140M
Co-investors: Andrew Adams (Oak HC/FT), Cristina Escoda (Tachyon Ventures), Martin Alexander Gershon (Endeavor Venture Funds)